Background
A question that often arises when attempting to interpret the observed efficacy of treatments within clinical trials, is whether the results of trials conducted in one country can be transferred to other countries or continents. The assumption is often made that differences in the efficacy of treatments between countries (or regions) will be neither negligible nor minor and therefore cannot be overlooked when assessing the potential benefit of treatments in one country (or region) on the basis of trials conducted in another country (or region) [1] [2] [3] . However, much of the justification for this sentiment comes from anecdotal evidence, the analysis of a very limited pool of data or the analysis of trial results that have not been obtained through a full systematic review [4] .
A popular way of statistically assessing heterogeneity in treatment effects within clinical trials is to perform a subgroup analysis [5] [6] [7] . Therefore, one approach to assessing differences in treatment efficacy between countries is to perform a subgroup analysis of a multinational trial with results broken down according to country [4, [8] [9] [10] [11] . However, one difficulty with such a strategy is that the data produced by a single large trial may not be sufficient to reveal such differences, even when they are genuinely quite large. Also, a quick literature search is sufficient to show that such between-country subgroup analyses are rarely published and the authors of the articles concerned may not be willing or able to hand over the required information when it is requested.
An alternative approach would be to compare the results of clinical trials conducted in one country with the results of similar trials conducted in another country, with the matching of trials determined by published systematic reviews; this is the approach that was explored in the present study. In particular, our aim was to assess differences in the results of randomized controlled trials (RCTs) between Europe and North America. This was achieved by categorizing RCTs within published systematic reviews according to the countries in which the trials were conducted. The clinical area that we focused on was cardiovascular disease (CVD); this specialty was chosen due to the rich variety of interventions that are commonly used to treat and prevent this disease (i.e. interventions ranging from the use of drugs, surgery and devices to changes to diet and lifestyle).
Two major obstacles need to be overcome when using systematic reviews to try to gauge the size of international differences in treatment efficacy: these differences are rarely assessed within the reviews themselves; and a comprehensive list of the countries in which each trial within any given review was conducted is rarely provided. Moreover, it is often the case that the country in which a trial took place is not reported even in the article that originally describes the principal findings of the trial. Therefore, without the kind of thorough search for country information that was carried out in the present study, it would be very difficult for a clinician or researcher to form a general picture about international variations in clinical efficacy over a wide range of different interventions.
Methods
A literature search of Medline and the Cochrane Library was conducted for all meta-analyses of RCTs indexed by the MESH term 'cardiovascular diseases'. Meta-analyses found through this search were included in this study if three criteria were satisfied. First, the meta-analyses had to have been published in the 9 years between January 2000 and December 2008 for the Cochrane Library search and in the 4 years between January 2005 and December 2008 for the Medline search. A longer search period was used for the Cochrane Library as it is a database that generally only contains metaanalyses that are the most up-to-date and of the highest quality and yet, as it is a much smaller database than Medline, it can be thoroughly searched without requiring an excessive amount of resources. The articles containing the meta-analyses had to be written in English.
Second, the patients taking part in the RCTs within each meta-analysis had to be adults. With regard to therapeutic interventions, the intervention had to be aimed at treating a problem with the heart or a blood vessel in the chest cavity. With regard to preventive interventions, the patients concerned had to have CVD or be at high risk of CVD.
Third, for at least one of the outcomes reported, results had to be combined over at least two trials published in or after 1990 that were conducted solely in Europe and at least two trials published in or after 1990 that were conducted solely in North America.
The countries in which trials were conducted were determined on the basis of what was stated in the articles that originally presented the trial results. If such country information was not given, then the country (or countries) where a trial was conducted was determined by contacting the authors directly or through the addresses of the authors themselves, but only if the authors were all based in the same country. North America was defined as the USA and Canada. Countries belonging to Europe were determined according to the definition of Europe used by the statistics division of the United Nations [12] . Trials published before 1990 were excluded in order to focus the study on the measurement of international differences in treatment efficacy that may presently exist, rather than the measurement of such differences in the past. No language restriction was placed on articles that originally presented trial results.
For each meta-analysis satisfying the above criteria, the most commonly reported fatal endpoint and non-fatal endpoint were determined. The rule used to achieve this was that in the meta-analysis concerned, more trials were combined over that fatal (non-fatal) endpoint than any other fatal (non-fatal) endpoint. For example, if for any given meta-analysis there were two non-fatal endpoints and five trials were combined over one of these endpoints while four trials were combined over the other endpoint, then the most commonly reported non-fatal endpoint for that metaanalysis would be defined as the former endpoint. Ties were settled by choosing the endpoint associated with the highest number of patients.
Within each meta-analysis, results for the selected endpoints were separately combined within North America and within Europe to give individual estimates of treatment efficacy both for North America and for Europe with respect to both a fatal and a non-fatal endpoint. However, this was only done if two conditions were satisfied. First, in relation to the given endpoint, a combined estimate of efficacy over all continents was presented as part of the meta-analysis concerned. Second, there were results from at least two trials in Europe and at least two trials in North America for the given endpoint.
The first condition ensured that this study carried out no truly new meta-analyses, but instead produced only new subgroup breakdowns for existing meta-analyses. The second condition allowed results to be combined using a random-effects model [13] . This is more than just a minor technical issue, as combining trial results using a random-effects rather than a fixed-effect model allows heterogeneity between trials conducted in the same continent or region to be taken into account. For example, if a trial conducted in Europe and a trial conducted in North America show vastly different results, it would be impossible to determine without further information whether, for instance, a second trial conducted in Europe would show similar results to the one conducted in North America. Clearly, there is the need for the results of at least two trials conducted in a given region in order to take account of such heterogeneity between trials within that region.
If an endpoint was event based and event rates were available, then trial results were combined over relative risks, even if trial results were reported in terms of odds ratios in the meta-analysis concerned. However, if event rates were not available and the meta-analysis reported trial results in terms of odds ratios, then trial results were combined over odds ratios. In other words, where possible, the relative risk was used to measure treatment efficacy.
It should be noted that although fatal and non-fatal endpoints were allowed to vary over different meta-analyses, the same fatal endpoint (e.g. cardiovascular death within 1 year) or non-fatal endpoint (e.g. non-fatal myocardial infarction within 1 year) was used to compare trials within any given meta-analysis. Therefore, since comparisons of trial results for Europe and North America were only conducted within individual meta-analyses, a large variation over different meta-analyses in the types of fatal and non-fatal endpoints being analysed was of only secondary concern.
Results
The literature search found 221 meta-analyses that satisfied the first and second inclusion criteria. Of these metaanalyses, 162 meta-analyses did not have the required number of trials published in or after 1990 in the relevant geographical areas for the third criterion to be satisfied. Although the exclusion of trials published before 1990 may seem to be quite a restrictive criterion, 179 of the initially identified 221 meta-analyses did not contain any trials published before 1990.
In summary, 59 meta-analyses were found that satisfied all the inclusion criteria of the study. Of these metaanalyses, 47 meta-analyses contained a sufficient number of trials to allow separate estimates of treatment efficacy for the most commonly reported fatal endpoints to be calculated both for Europe and for North America. Details regarding these meta-analyses are given in Tables 1 and 2 . On the other hand, 44 out of the 59 meta-analyses included in the study contained a sufficient number of trials to allow such estimates to be calculated with respect to the most commonly reported non-fatal endpoints. These metaanalyses are listed in Tables 3-5 .
Although there are no two meta-analyses in Tables 1-5 that are based on exactly the same set of trials, it is clear that some of the meta-analyses in these tables addressed similar clinical questions and therefore could be thought of as 'overlapping' with each other. For meta-analyses with fatal endpoints, there are 29 meta-analyses that could be described as overlapping . By 'overlapping', it is meant that any one of these meta-analyses shares some trial results with at least one other of these metaanalyses, to the extent that the estimates produced by these meta-analyses may be regarded as being to some degree not independent of one another. For meta-analyses with non-fatal endpoints, there are 23 such overlapping metaanalyses [17, 19, 20, [26] [27] [28] [30] [31] [32] [33] 35, [38] [39] [40] [41] [43] [44] [45] [46] [47] [48] [49] [50] . Therefore, there are 18 meta-analyses with fatal endpoints [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] and 21 meta-analyses with non-fatal endpoints [15, 22, 25, 42, [52] [53] [54] [55] 57, 59, [61] [62] [63] [64] [66] [67] [68] [69] [70] [71] [72] that are nonoverlapping in the sense just outlined.
In terms of what was in each case the most commonly reported fatal endpoint, there are 28 meta-analyses where, relative to the control, the intervention is more favoured in Europe than North America, 15 meta-analyses where the intervention is more favoured in North America than Europe and four meta-analyses where the intervention and control groups were not identified (i.e. one treatment group was simply compared with another treatment group). Using a binomial test under the null hypothesis that the efficacy of interventions relative to controls is the same in both Europe and North America, the ratio of 28 to 15 is not statistically significant at the 5% level (P = 0.066).
Within individual meta-analyses, the difference in treatment efficacy between Europe and North America in terms of the most commonly reported fatal endpoint is statistically significant at the 5% level in one meta-analysis [30] . However, given that there are 47 meta-analyses with fatal endpoints, finding one difference that is statistically significant at the 5% level among the 47 differences assessed is not more than would be expected by random chance alone.
In terms of what was in each case the most commonly reported non-fatal endpoint, there are 28 meta-analyses where, relative to the control, the intervention is more favoured in Europe than North America, 12 meta-analyses where the intervention is more favoured in North America than Europe and, again, four meta-analyses where the intervention and control groups were not identified. Using the same binomial test as outlined earlier, the ratio of 28 to 12 is statistically significant at the 5% level (P = 0.017). Therefore, with respect to non-fatal endpoints, there is some evidence that, relative to controls, interventions are more favoured in Europe than North America.
Within individual meta-analyses, the difference in treatment efficacy between Europe and North America in terms of the most commonly reported non-fatal endpoint is statistically significant at the 5% level in two meta-analyses [26, 36] . However, given that there are 44 meta-analyses with non-fatal endpoints, finding that two meta-analyses give statistically significant results at the 5% level, in the manner just described, again does not demonstrate the existence of intercontinental differences, as this is not a greater number of meta-analyses than would be expected by random chance alone.
In trying to explain the result that, in terms of nonfatal endpoints, interventions appear to be more favoured in Europe than North America, the possibility that this result may be due to the 'double counting' of trials needs to be assessed. It has already been mentioned that among meta-analyses that overlap in terms of the clinical question being addressed, some trial results are used in more than one meta-analysis. If, among these trials, a higher than average proportion of interventions are more favoured in a Region where intervention performs best relative to the control (according to the data collected). The P value is for the difference in the estimates of the odds ratio between Europe and North America (under the null hypothesis of no difference). b The intervention and control groups are not identified for these meta-analyses (i.e. one treatment group is simply compared with another treatment group). ACS: acute coronary syndrome; AF: atrial fibrillation; applic.: applicable; CABG: coronary artery bypass graft; CAD: coronary artery disease; CHD: coronary heart disease; CHF: congestive heart failure; CI: confidence interval; CRT: cardiac resynchronization therapy; CVD: cardiovascular disease; HF: heart failure; MI: myocardial infarction; N. Amer.: North America; PCI: percutaneous coronary intervention; TIMI: thrombolysis in myocardial infarction. a Region where intervention performs best relative to the control (according to the data collected). The P value is for the difference in the estimates of the relative risk between Europe and North America (under the null hypothesis of no difference). b The intervention and control groups are not identified for these meta-analyses (i.e. one treatment group is simply compared with another treatment group). a Region where intervention performs best relative to the control (according to the data collected). The P value is for the difference in the estimates of the odds ratio between Europe and North America (under the null hypothesis of no difference). b The intervention and control groups are not identified for these meta-analyses (i.e. one treatment group is simply compared with another treatment group). Europe than North America, then when all meta-analyses are aggregated together, there will be disproportionately strong support for the theory that interventions are favoured more in Europe than North America. However, in terms of what was in each case the most commonly reported non-fatal endpoint, the percentage of meta-analyses where, relative to the control, the intervention is more favoured in Europe than North America is 70% both for meta-analyses that were earlier identified as overlapping and for those that were identified as non-overlapping (i.e. in both cases there are 14 out of 20 meta-analyses where the intervention is more favoured in Europe than North America). Therefore, with respect to non-fatal endpoints, there is no evidence that the overall percentage of meta-analyses where the intervention is more favoured in Europe than North America (i.e. 70%; 28/40 meta-analyses) has been inappropriately inflated due to the type of double counting of trial results discussed above.
In terms of what was in each case the most commonly reported fatal endpoint, the percentage of meta-analyses where, relative to the control, the intervention is more favoured in Europe than North America is 73% for metaanalyses that were earlier identified as overlapping (i.e. 19/26 meta-analyses), but only 53% for meta-analyses that were identified as non-overlapping (i.e. 9/17 metaanalyses). Therefore, with respect to fatal endpoints, there is some evidence that the large (but not statistically significant) percentage of meta-analyses where the intervention is more favoured in Europe than North America, (i.e. 65%; 28/43 meta-analyses) may be at least partially due to the type of double counting of trial results discussed above.
Discussion
There is no evidence in this study to support the theory that, for fatal endpoints, there are systematic differences in trial results between Europe and North America. On the other hand, for non-fatal endpoints, there is some evidence to support the theory that relative to controls, interventions are more favoured in trials conducted in Europe than in North America. However, it is not possible, on the basis of the study data, to determine for which types of intervention these intercontinental differences in trial results for non-fatal endpoints are likely to be more pronounced than others. This is because, for both fatal and non-fatal endpoints, the proportion of times that within individual meta-analyses the difference in treatment efficacy between Europe and North America is statistically significant at the 5% level is not more than would be expected by random chance alone. The lack of evidence for intercontinental differences produced by this latter analysis may be surprising given the large amount of data that has been collected.
The potential sources of bias in this study can be categorized into those that should have been controlled for within the meta-analyses that form the raw data of the study and those that generally lie outside of this type of control. Variations in treatment regimen and patient characteristics and the exclusion of poorly conducted trials should all technically be allowed for and dealt with by a good-quality meta-analysis, although, of course, there may be many deficiencies in this respect. There may also be, for example, a tendency in some countries to only carry out RCTs of new treatments on subgroups of patients who may be expected to benefit more from new treatments than the type of patients who generally participate in clinical trials in other countries.
A type of bias that is often very difficult to allow for in a meta-analysis is publication bias. An interpretation of the results of this study in terms of the presence of this type of bias would be that trials that appear in systematic reviews are more likely to suffer from publication bias if they were conducted in Europe rather than in North America. The theory here would be that trial results that either favour the control rather than the intervention or are not strongly favourable towards the intervention are less likely to be published if the trials concerned were conducted in Europe rather than in North America. However, the presence of publication bias in a meta-analysis of only European trials would cause as much of a problem in determining what is the best treatment in a European context as it would in trying to use the same results to decide upon the best treatment in a North American context. In both contexts, we need to place some faith in published trial results in order to be able to utilize the empirical evidence that is available.
Of course another interpretation of the results of this study is that potential biases within the source data did not greatly affect these results, and the observation that, for non-fatal endpoints, interventions appear to be more favoured in trials conducted in Europe than in North America is in fact a consequence of the existence of a 'genuine' intercontinental difference. In other words, maybe it is the case, for example, that European health care policy creates an environment where, in comparison with North America, new and innovative treatments are more likely to perform better than standard treatments, which, of course, are likely to be the control treatments in RCTs.
A reason why evidence has been found for the existence of intercontinental differences in trial results with regard to non-fatal endpoints, but not with regard to fatal endpoints, is that real differences also exist for fatal endpoints, it is just that the noise-to-signal ratio is much higher when estimating efficacy in terms of fatal rather than non-fatal endpoints and therefore there are insufficient data to be able to observe these differences. This is consistent with the result, already noted, that in terms of fatal endpoints, the percentage of meta-analyses where, relative to the control, the intervention is more favoured in Europe than in North America is 65%, although the difference of this percentage from 50% is not quite statistically significant (P = 0.066). A low signalto-noise ratio may also explain why the number of times that intercontinental differences are statistically significant at the 5% level within individual meta-analyses is not more than would be expected by chance alone for both fatal and non-fatal endpoints.
Another reason for the difference in the results between fatal and non-fatal endpoints is that judging whether a nonfatal endpoint has occurred can be much more subjective than judging whether a fatal endpoint has occurred. Therefore, if there is a tendency for poorly regulated trials to be biased in favour of the intervention rather than the control, then this bias is more likely to reveal itself with respect to a non-fatal rather than a fatal endpoint. This provides some grounds for speculating that trials in Europe, when averaged over all countries in Europe, may not be as well regulated as trials in North America.
The main strengths of this study were the amount of data collected and the methodology used to supplement and analyze this data, e.g. using published systematic reviews in order to match up trials, conducting a thorough search to determine the countries in which trials were carried out and adjusting for heterogeneity between the results of trials conducted in the same continent. In particular, the potential for finding spurious international differences in trial results, which may have been found in other studies [3] , was reduced by the fact that a random-effects model was used to allow for this latter type of heterogeneity. Also, the matching up of trials through the use of published systematic reviews avoided the type of pragmatic strategies for comparing trials between countries that have been used by other researchers [73, 74] . The task of performing this kind of study in the future would clearly be made easier if researchers preparing the results of trials or systematic reviews for publication were willing to be more explicit about the countries in which trials have taken place.
An aspect of this study that could be identified as being a weakness is that the huge aggregation of data made it difficult to identify factors that may be causing intercontinental differences and to determine between which specific regions these differences are likely to be more pronounced than the overall average. As a consequence, it should be pointed out that the results of this study do not directly provide grounds for being more sceptical about claims of effectiveness that are based on RCTs conducted in specific countries in Europe rather than in North America, e.g. this study provides no direct grounds for being more sceptical about RCTs conducted in the UK or France rather than in the USA. However, the aggregation of data was necessary in order to combat the low signal-to-noise ratio mentioned above and to be able at least to draw some kind of general conclusions about differences in clinical trials between regions. Furthermore, although this data aggregation was performed on the basis of a longer search period for the Cochrane Library (2000-2008) than for Medline (2005) (2006) (2007) (2008) , it should be noted, along with the justification for this design feature made in the Methods section, that only five meta-analyses [17, 57, 58, 62, 71] entered the present study as a result of the search of the Cochrane Library from 2000 to 2004.
Another potential weakness of the study that could be highlighted is that although, unlike other studies, this study combined information from many different trials, it did not attempt to extract patient-level information from trials that had arms in both Europe and North America. It would be expected that a researcher carrying out an international trial would at least check for differences in treatment efficacy between patients based on the country where they participated in the trial. However, as mentioned previously, it is very much the exception rather than the rule for the results of these analyses to be published. More importantly, the present study was designed to provide information to help to try to assess what the likely outcome would be if a completely new trial of a given treatment was conducted in an, as yet, untested region for the treatment on the basis of the results of older trials conducted in other regions. This assessment, or rather the definitiveness of this assessment, would determine whether it is worth waiting for the outcome of this trial before approving or not approving the use of the treatment in the region concerned.
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